Predict your next investment

FINANCIAL | Investment Firms & Funds
sunnymeath.net

See what CB Insights has to offer

Stage

Acquired | Acquired

About Sunnymeath Asset Management

Sunnymeath Asset Management is a boutique investment firm that analyzes and manages equity and fixed income securities. The firm provides individualized equity, balanced and fixed income account management which capitalizes on market opportunities in a variety of asset classes and sectors.

Sunnymeath Asset Management Headquarter Location

151 Bodman Place Suite 401

Red Bank, New Jersey, 07701,

United States

732-933-8444

Latest Sunnymeath Asset Management News

Merck & Co. (MRK) Stake Maintained by Sunnymeath Asset Management Inc.

Sep 18, 2016

Tweet Sunnymeath Asset Management Inc. maintained its position in Merck & Co. (NYSE:MRK) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,810 shares of the company’s stock at the end of the second quarter. Sunnymeath Asset Management Inc.’s holdings in Merck & Co. were worth $105,000 at the end of the most recent reporting period. Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Americafirst Capital Management LLC purchased a new position in Merck & Co. during the second quarter worth about $115,000. Keel Point LLC purchased a new position in Merck & Co. during the second quarter worth about $204,000. Carlson Capital Management purchased a new position in Merck & Co. during the second quarter worth about $217,000. Indiana Trust & Investment Management CO purchased a new position in Merck & Co. during the second quarter worth about $220,000. Finally, NorthRock Partners LLC increased its position in Merck & Co. by 1.2% in the first quarter. NorthRock Partners LLC now owns 3,862 shares of the company’s stock worth $206,000 after buying an additional 45 shares in the last quarter. Institutional investors and hedge funds own 72.94% of the company’s stock. Merck & Co. ( NYSE:MRK ) traded down 0.16% during trading on Friday, reaching $62.28. The company’s stock had a trading volume of 12,432,293 shares. The firm has a market capitalization of $172.22 billion, a P/E ratio of 34.16 and a beta of 0.63. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.00. The firm has a 50-day moving average price of $61.95 and a 200-day moving average price of $57.17. Merck & Co. (NYSE:MRK) last posted its earnings results on Friday, July 29th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.02. The company earned $9.84 billion during the quarter, compared to analyst estimates of $9.79 billion. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The business’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 earnings per share. On average, equities analysts anticipate that Merck & Co. will post $3.75 EPS for the current fiscal year. The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend is Tuesday, September 13th. Merck & Co.’s dividend payout ratio (DPR) is 101.10%. A number of research firms recently issued reports on MRK. Credit Suisse Group AG upgraded Merck & Co. from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $62.00 to $73.00 in a research note on Sunday, August 7th. Piper Jaffray Cos. restated a “neutral” rating and set a $62.00 price target (up previously from $58.00) on shares of Merck & Co. in a research note on Monday, August 8th. Deutsche Bank AG raised their price target on Merck & Co. from $58.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, August 8th. Jefferies Group raised their price target on Merck & Co. from $53.00 to $57.00 and gave the stock a “hold” rating in a research note on Monday, August 8th. Finally, Barclays PLC raised their price target on Merck & Co. from $66.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, September 9th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of €63.31 ($70.34). In related news, EVP Adam H. Schechter sold 39,200 shares of the stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total value of €2,454,312.00 ($2,727,013.33). Following the completion of the transaction, the executive vice president now directly owns 39,200 shares of the company’s stock, valued at approximately €2,454,312 ($2,727,013.33). The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . Also, CEO Kenneth C. Frazier sold 60,000 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of €58.00 ($64.44), for a total value of €3,480,000.00 ($3,866,666.67). Following the completion of the transaction, the chief executive officer now directly owns 554,856 shares of the company’s stock, valued at €32,181,648 ($35,757,386.67). The disclosure for this sale can be found here . 0.05% of the stock is owned by corporate insiders. Merck & Co. Company Profile Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK). Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter . Comment on this Post

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.